Published in Anal Biochem on December 25, 2007
Metabolism of peptide reporters in cell lysates and single cells. Analyst (2012) 1.00
Integrated microfluidic and imaging platform for a kinase activity radioassay to analyze minute patient cancer samples. Cancer Res (2010) 0.98
Peptide reporters of kinase activity in whole cell lysates. Biopolymers (2010) 0.98
A peptide-based biosensor assay to detect intracellular Syk kinase activation and inhibition. Biochemistry (2012) 0.89
A bead-based activity screen for small-molecule inhibitors of signal transduction in chronic myelogenous leukemia cells. Mol Cancer Ther (2010) 0.87
A magnetic bead-based protein kinase assay with dual detection techniques. Anal Biochem (2010) 0.84
A peptide photoaffinity probe specific for the active conformation of the Abl tyrosine kinase. Chembiochem (2012) 0.81
(124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo. J Nucl Med (2010) 0.81
Cell treatment and lysis in 96-well filter-bottom plates for screening Bcr-Abl activity and inhibition in whole-cell extracts. J Biomol Screen (2010) 0.79
Photocleavable peptide-oligonucleotide conjugates for protein kinase assays by MALDI-TOF MS. Mol Biosyst (2012) 0.78
A multiple reaction monitoring (MRM) method to detect Bcr-Abl kinase activity in CML using a peptide biosensor. PLoS One (2013) 0.77
Photocleavable peptide-conjugated magnetic beads for protein kinase assays by MALDI-TOF MS. Bioconjug Chem (2010) 0.76
Gleevec shifts APP processing from a β-cleavage to a nonamyloidogenic cleavage. Proc Natl Acad Sci U S A (2017) 0.75
Activity assay of epidermal growth factor receptor tyrosine kinase inhibitors in triple-negative breast cancer cells using peptide-conjugated magnetic beads. Assay Drug Dev Technol (2012) 0.75
A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen (1999) 32.67
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 20.30
Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (1973) 15.28
Light-directed, spatially addressable parallel chemical synthesis. Science (1991) 15.09
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med (1996) 13.49
Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 11.83
Printing proteins as microarrays for high-throughput function determination. Science (2000) 10.77
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell (2005) 7.99
Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature (1995) 6.16
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res (2002) 4.19
The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science (1986) 3.53
Peptide chips for the quantitative evaluation of protein kinase activity. Nat Biotechnol (2002) 3.05
Autoinhibition of c-Abl. Cell (2002) 1.93
A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin Cancer Res (2003) 1.83
Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol (2004) 1.83
Applications of peptide arrays prepared by the SPOT-technology. Curr Opin Biotechnol (2001) 1.79
Therapeutic cancer targeting peptides. Biopolymers (2002) 1.70
Peptide and small molecule microarray for high throughput cell adhesion and functional assays. Bioconjug Chem (2001) 1.65
Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene (2002) 1.38
Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J Med Chem (1997) 1.38
Protein and peptide arrays: recent trends and new directions. Biomol Eng (2006) 1.34
Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res (2002) 1.34
Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors. J Med Chem (1998) 1.31
Peptide arrays: from macro to micro. Curr Opin Biotechnol (2002) 1.26
Rational design of specific high-affinity peptide ligands for the Abl-SH3 domain. Biochemistry (1996) 1.19
Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol (2005) 1.12
New tyrosine kinase inhibitors in chronic myeloid leukemia. Haematologica (2005) 1.04
Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. Cancer Res (2003) 1.04
Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia (2005) 1.03
Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies. Ann Hematol (1999) 1.02
Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571. Blood (2001) 1.01
2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. J Med Chem (1998) 0.98
Peptide arrays for kinase profiling. Chembiochem (2005) 0.97
Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Cancer Cell (2002) 0.97
Protein-acrylamide copolymer hydrogels for array-based detection of tyrosine kinase activity from cell lysates. Biomacromolecules (2005) 0.96
Treating imatinib-resistant leukemia: the next generation targeted therapies. ScientificWorldJournal (2006) 0.91
ABL-BCR expression in BCR-ABL-positive human leukemia cell lines. Leuk Res (1999) 0.89
Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors. J Med Chem (1998) 0.87
Standardization of an enzyme-linked immunosorbent assay for the determination of protein tyrosine kinase activity. Anal Biochem (1993) 0.86
Analysis of heregulin-induced ErbB2 phosphorylation with a high-throughput Kinase receptor activation enzyme-linked immunosorbant assay. Anal Biochem (1996) 0.82
The second generation of BCR-ABL tyrosine kinase inhibitors. Int J Hematol (2006) 0.81
Adsorption of plasma proteins onto polymer latices. Adv Colloid Interface Sci (1991) 0.80
Immunoassay protocol for quantitation of protein kinase activities. Methods Enzymol (2000) 0.79
Peptide and small-molecule microarrays. Methods Mol Biol (2005) 0.79
Overcoming drug resistance in chronic myeloid leukemia. Curr Opin Hematol (2006) 0.77
Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell (2003) 5.44
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest (2007) 5.17
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res (2002) 4.19
Binding of chromatin-modifying activities to phosphorylated histone H2A at DNA damage sites. Mol Cell (2004) 4.17
Peptide chips for the quantitative evaluation of protein kinase activity. Nat Biotechnol (2002) 3.05
Role of Dot1-dependent histone H3 methylation in G1 and S phase DNA damage checkpoint functions of Rad9. Mol Cell Biol (2005) 2.48
Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci U S A (2003) 2.44
Science education. Educating future scientists. Science (2003) 1.97
Synthesis enables identification of the cellular target of leucascandrolide A and neopeltolide. Nat Chem Biol (2008) 1.83
Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J Biol Chem (2003) 1.79
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci U S A (2006) 1.71
Cdc14 phosphatases preferentially dephosphorylate a subset of cyclin-dependent kinase (Cdk) sites containing phosphoserine. J Biol Chem (2011) 1.68
NuA4 subunit Yng2 function in intra-S-phase DNA damage response. Mol Cell Biol (2002) 1.51
Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res (2002) 1.34
Yeast G1 DNA damage checkpoint regulation by H2A phosphorylation is independent of chromatin remodeling. Proc Natl Acad Sci U S A (2006) 1.32
Sensing, signalling and integrating physical processes during Saccharomyces cerevisiae invasive and filamentous growth. Microbiology (2002) 1.32
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc Natl Acad Sci U S A (2006) 1.30
Caenorhabditis elegans ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation. Nat Genet (2004) 1.29
A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood (2004) 1.29
CDK-dependent Hsp70 Phosphorylation controls G1 cyclin abundance and cell-cycle progression. Cell (2012) 1.29
Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors. Cancer Res (2010) 1.22
Epigenetic modifications in double-strand break DNA damage signaling and repair. Clin Cancer Res (2010) 1.18
Asynchronous cell cycle and asymmetric vacuolar inheritance in true hyphae of Candida albicans. Eukaryot Cell (2003) 1.18
Bcl-x(L) complements Saccharomyces cerevisiae genes that facilitate the switch from glycolytic to oxidative metabolism. J Biol Chem (2002) 1.16
Yeast cell death during DNA damage arrest is independent of caspase or reactive oxygen species. J Cell Biol (2004) 1.11
Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation. Mol Cancer Ther (2011) 1.08
Depression of Saccharomyces cerevisiae invasive growth on non-glucose carbon sources requires the Snf1 kinase. Mol Microbiol (2002) 1.07
Robust G1 checkpoint arrest in budding yeast: dependence on DNA damage signaling and repair. J Cell Sci (2002) 1.06
Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. PLoS Comput Biol (2009) 1.04
Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. Cancer Res (2003) 1.04
Marker-fusion PCR for one-step mutagenesis of essential genes in yeast. Yeast (2002) 1.01
CDK Pho85 targets CDK inhibitor Sic1 to relieve yeast G1 checkpoint arrest after DNA damage. Nat Struct Mol Biol (2006) 1.00
A peptide biosensor for detecting intracellular Abl kinase activity using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal Biochem (2009) 0.99
A pairwise chemical genetic screen identifies new inhibitors of glucose transport. Chem Biol (2011) 0.99
Peptide reporters of kinase activity in whole cell lysates. Biopolymers (2010) 0.98
Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib. Mol Cancer Res (2010) 0.98
Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor. Clin Cancer Res (2014) 0.97
Relevance and irrelevance of DNA damage response to radiotherapy. DNA Repair (Amst) (2004) 0.97
Investigating quantitation of phosphorylation using MALDI-TOF mass spectrometry. J Mass Spectrom (2008) 0.97
Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib. J Med Chem (2007) 0.97
Ataxia telangiectasia-mutated (ATM) kinase activity is regulated by ATP-driven conformational changes in the Mre11/Rad50/Nbs1 (MRN) complex. J Biol Chem (2013) 0.96
A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer. Neoplasia (2009) 0.96
Protein-acrylamide copolymer hydrogels for array-based detection of tyrosine kinase activity from cell lysates. Biomacromolecules (2005) 0.96
PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood (2005) 0.94
Phosphatidylinositol 3-kinase and Src family kinases are required for phosphorylation and membrane recruitment of Dok-1 in c-Kit signaling. J Biol Chem (2002) 0.92
Radiation-inducible immunotherapy for cancer: senescent tumor cells as a cancer vaccine. Mol Ther (2012) 0.92
Direct evidence that Bcr-Abl tyrosine kinase activity disrupts normal synergistic interactions between Kit ligand and cytokines in primary primitive progenitor cells. Mol Cancer Res (2003) 0.89
A peptide-based biosensor assay to detect intracellular Syk kinase activation and inhibition. Biochemistry (2012) 0.89
Use of protein-acrylamide copolymer hydrogels for measuring protein concentration and activity. Anal Biochem (2004) 0.89
Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors. Nucl Med Biol (2005) 0.89
Time-resolved luminescence detection of spleen tyrosine kinase activity through terbium sensitization. Anal Chem (2013) 0.88
Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci U S A (2012) 0.87
An essential function of yeast cyclin-dependent kinase Cdc28 maintains chromosome stability. J Biol Chem (2002) 0.87
A bead-based activity screen for small-molecule inhibitors of signal transduction in chronic myelogenous leukemia cells. Mol Cancer Ther (2010) 0.87
Assaying Bcr-Abl kinase activity and inhibition in whole cell extracts by phosphorylation of substrates immobilized on agarose beads. Anal Biochem (2005) 0.86
Photocleavable peptide hydrogel arrays for MALDI-TOF analysis of kinase activity. Analyst (2006) 0.86
Detection of early Abl kinase activation after ionizing radiation by using a peptide biosensor. Chembiochem (2012) 0.86
Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells. Proteomics (2006) 0.85
Fluorescence lifetime imaging of biosensor peptide phosphorylation in single live cells. Angew Chem Int Ed Engl (2013) 0.85
Quantifying the sensitivities of EGF receptor (EGFR) tyrosine kinase inhibitors in drug resistant non-small cell lung cancer (NSCLC) cells using hydrogel-based peptide array. Biosens Bioelectron (2010) 0.84
A magnetic bead-based protein kinase assay with dual detection techniques. Anal Biochem (2010) 0.84
A time-resolved luminescence biosensor assay for anaplastic lymphoma kinase (ALK) activity. Chem Commun (Camb) (2014) 0.83
Dissection of Rad9 BRCT domain function in the mitotic checkpoint response to telomere uncapping. DNA Repair (Amst) (2009) 0.83
KINATEST-ID: a pipeline to develop phosphorylation-dependent terbium sensitizing kinase assays. J Am Chem Soc (2015) 0.83
Cellular response to DNA damage. Ann N Y Acad Sci (2005) 0.82
Non-catalytic function for ATR in the checkpoint response. Cell Cycle (2007) 0.82
Phosphoprotein profiling by PA-GeLC-MS/MS. J Proteome Res (2008) 0.81
Optimizing thiophosphorylation in the presence of competing phosphorylation with MALDI-TOF-MS detection. J Proteome Res (2005) 0.81
(124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo. J Nucl Med (2010) 0.81
Control of the yeast cell cycle with a photocleavable alpha-factor analogue. Angew Chem Int Ed Engl (2006) 0.81
Fluorine-labeled dasatinib nanoformulations as targeted molecular imaging probes in a PDGFB-driven murine glioblastoma model. Neoplasia (2012) 0.81
Rapid validation of Mascot search results via stable isotope labeling, pair picking, and deconvolution of fragmentation patterns. Mol Cell Proteomics (2009) 0.81
Cell treatment and lysis in 96-well filter-bottom plates for screening Bcr-Abl activity and inhibition in whole-cell extracts. J Biomol Screen (2010) 0.79
Design and implementation of algorithms for focus automation in digital imaging time-lapse microscopy. Cytometry (2002) 0.79
A general strategy for studying multisite protein phosphorylation using label-free selected reaction monitoring mass spectrometry. Anal Biochem (2011) 0.78
Monitoring changes in the subcellular location of proteins in S. cerevisiae. Methods Mol Biol (2004) 0.78
Photocleavable peptide-oligonucleotide conjugates for protein kinase assays by MALDI-TOF MS. Mol Biosyst (2012) 0.78
Kinase activation in circulating cells: opportunities for biomarkers for diagnosis and therapeutic monitoring. Expert Opin Med Diagn (2008) 0.78
Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett (2009) 0.78
A multiple reaction monitoring (MRM) method to detect Bcr-Abl kinase activity in CML using a peptide biosensor. PLoS One (2013) 0.77
DNA resection proteins Sgs1 and Exo1 are required for G1 checkpoint activation in budding yeast. DNA Repair (Amst) (2013) 0.77
Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors. BMC Cancer (2012) 0.77
Akt2 inhibits the activation of NFAT in lymphocytes by modulating calcium release from intracellular stores. Cell Signal (2012) 0.76
DNA photocleavage and biological activity of a pyrene dihydrodioxin. Bioorg Med Chem Lett (2005) 0.76
Annotator: postprocessing software for generating function-based signatures from quantitative mass spectrometry. J Proteome Res (2012) 0.76
Photocleavable peptide-conjugated magnetic beads for protein kinase assays by MALDI-TOF MS. Bioconjug Chem (2010) 0.76